Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + tivumecirnon
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + tivumecirnon is a combination therapy consisting of pembrolizumab, a PD-1 inhibitor, and tivumecirnon (FLX475), a selective CCR4 antagonist. Tivumecirnon is designed to block the migration of regulatory T cells (Tregs) into tumors, thereby preventing immunosuppression in the tumor microenvironment. When combined with pembrolizumab, which blocks the PD-1 pathway, this dual approach aims to enhance anti-tumor immunity by both preventing Treg-mediated immunosuppression and reinvigorating exhausted T cells. The combination has shown promising activity in several cancer types, particularly in virus-associated cancers such as EBV-positive gastric cancer and HPV-positive head and neck squamous cell carcinoma.
- Brand names
- Keytruda + tivumecirnon
- Other names
- tivumecirnon + pembrolizumab
02
Targets
CCR4 (C-C Motif Chemokine Receptor 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + tivumecirnon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + tivumecirnon.